Dengue Viruses and Lifelong Immunity: Reevaluating the Conventional Wisdom

Journal of Infectious Diseases

Volumn 214, Issue 7, 2016, Pages 979-981

  Forshey, Brett M ^a,b   Stoddard, Steven T ^c   Morrison, Amy C ^d  

^a Global Emerging Infections Surveillance and Response Section   (United States)

^b Armed Forces Health Surveillance Center (AFHSC) Cherokee Nation Technology Solutions Inc   (United States)

^c SAN DIEGO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

dengue; epidemiology; homotypic immunity; vaccine sterile immunity; virus neutralization

Indexed keywords

DENGUE VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; HUMAN; NONHUMAN; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REINFECTION; VACCINATION; VIRUS TRANSMISSION; DENGUE VIRUS; IMMUNOLOGY; SERODIAGNOSIS;

ANTIBODIES, VIRAL; DENGUE; DENGUE VACCINES; DENGUE VIRUS; HUMANS; NEUTRALIZATION TESTS;

EID: 84994104582     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw102     Document Type: Note

References (26)

1. Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 2011; 29:587-619.
2. Imrie A, Meeks J, Gurary A, et al. Antibody to dengue 1 detected more than 60 years after infection. Viral Immunol 2007; 20:672-5.
3. Halstead SB. Neutralization and antibodydependent enhancement of dengue viruses. Adv Virus Res 2003; 60:421-67.
4. Capeding MR, Tran NH, Hadinegoro SRS, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebocontrolled trial. Lancet 2014; 384:1358-65.
5. Hadinegoro SR, Arredondo-García JL, Capeding MR, et al. Efficacy and long-Term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015; 373:1195-206.
6. Guy B, Jackson N. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol 2016; 14:45-54.
7. Wilder-Smith A. Dengue vaccines: dawning at last? Lancet (London, England) 2014; 384:1327-9.
8. Sabin AB. Research on dengue during World War II. Am J Trop Med Hyg 1952; 1:30-50.
9. Halstead SB. Etiologies of the experimental dengues of Siler and Simmons. Am J Trop Med Hyg 1974; 23:974-82.
10. Kochel TJ, Watts DM, Halstead SB, et al. Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet 2002; 360:310-2.
11. Bernardo L, Izquierdo A, Prado I, et al. Primary and secondary infections of Macaca fascicularis monkeys with Asian and American genotypes of dengue virus 2. Clin Vaccine Immunol 2008; 15:439-46.
12. Forshey BM, Reiner RC, Olkowski S, et al. Incomplete protection against dengue virus type 2 reinfection in Peru. PLoS Negl Trop Dis 2016; 10: e0004398.
13. Wahala WMPB, de Silva AM. The human antibody response to dengue virus infection. Viruses 2011; 3:2374-95.
14. Endy TP, Nisalak A, Chunsuttitwat S, et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 2004; 189:990-1000.
15. Brien JD, Austin SK, Sukupolvi-Petty S, et al. Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol 2010; 84:10630-43.
16. WahalaWMPB, Donaldson EF, de Alwis R, Accavitti-Loper MA, Baric RS, de Silva AM. Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog 2010; 6:e1000821.
17. Katzelnick LC, Fonville JM, Gromowski GD, et al. Dengue viruses cluster antigenically but not as discrete serotypes. Science 2015; 349: 1338-43.
18. Sharp TM, Hunsperger E, Muñoz-Jordán JL, Margolis HS, Tomashek KM. Sequential episodes of dengue-Puerto Rico, 2005-2010. Am J Trop Med Hyg 2014; 91:235-9.
19. Wang C, Katzelnick LC, Montoya M, Hue KDT, Simmons CP, Harris E. Evolutionarily successful Asian 1 dengue virus 2 lineages contain one substitution in envelope that increases sensitivity to polyclonal antibody neutralization. J Infect Dis 2015; 213:975-84.
20. Duong V, Lambrechts L, Paul RE, et al. Asymptomatic humans transmit dengue virus to mosquitoes. Proc Natl Acad Sci USA 2015; 112: 14688-93.
21. Nguyet MN, Duong THK, Trung VT, et al. Host and viral features of human dengue cases shape the population of infected and infectious Aedes aegypti mosquitoes. Proc Natl Acad Sci USA 2013; 110: 9072-7.
22. OhAinle M, Balmaseda A, Macalalad AR, et al. Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-Specific immunity. Sci Transl Med 2011; 3: 114ra128.
23. Wearing HJ, Rohani P. Ecological and immunological determinants of dengue epidemics. Proc Natl Acad Sci USA 2006; 103:11802-7.
24. Velumani S, Toh YX, Balasingam S, et al. Low antibody titers five years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naïve vaccinees. Hum Vaccin Immunother 2016; doi:10.1080/21645515.2015.1126012.
25. Durbin AP, Whitehead SS. The dengue human challenge model: has the time come to accept this challenge? J Infect Dis 2013; 207:697-9.
26. Lyons AG. The human dengue challenge experience at the Walter Reed Army Institute of Research. J Infect Dis 2014; 209(suppl):S49-55.